Nyotran: Phase II data; Phase III

In a Phase II trial of 24 patients with definite or probable Aspergillus infections, treatment with 4 mg/kg/day of Nyotran gave 6 objective responses among 19 evaluable patients. Of the 16 evaluable patients who were refractory to amphotericin B, 7 were alive one month following Nyotran treatment. Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto. ARNX said it expects to submit in 2001 an NDA for Nyotran. ...